Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Nov 1;8(4):254-263.
doi: 10.2174/157339412804143113.

DNA Vaccines for Prostate Cancer

Douglas G McNeel  1 , Jordan T Becker  1 , Laura E Johnson  1 , Brian M Olson  1
Affiliations

DNA Vaccines for Prostate Cancer

Douglas G McNeel et al. Curr Cancer Ther Rev. .

Abstract

Delivery of plasmid DNA encoding an antigen of interest has been demonstrated to be an effective means of immunization, capable of eliciting antigen-specific T cells. Plasmid DNA vaccines offer advantages over other anti-tumor vaccine approaches in terms of simplicity, manufacturing, and possibly safety. The primary disadvantage is their poor transfection efficiency and subsequent lower immunogenicity relative to other genetic vaccine approaches. However, multiple preclinical models demonstrate anti-tumor efficacy, and many efforts are underway to improve the immunogenicity and anti-tumor effect of these vaccines. Clinical trials using DNA vaccines as treatments for prostate cancer have begun, and to date have demonstrated safety and immunological effect. This review will focus on DNA vaccines as a specific means of antigen delivery, advantages and disadvantages of this type of immunization, previous experience in preclinical models and human trials specifically conducted for the treatment of prostate cancer, and future directions for the application of DNA vaccines to prostate cancer immunotherapy.

Keywords: DNA vaccines; clinical trials; prostate cancer; tumor antigens.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST

The author(s) confirm that this article content has no conflicts of interest.

References

    1. Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–23. - PMC - PubMed
    1. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Peuson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411–22. - PubMed
    1. Higano CS, Corman JM, Smith DC. Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer. 2008;113:975–84. - PubMed
    1. Emens LA. GM-CSF-secreting vaccines for solid tumors. Curr Opin Investig Drags. 2009;10:1315–24. - PubMed
    1. Wolff JA, Malone RW, Williams P, Chong, et al. Direct gene transfer into mouse muscle in vivo. Science. 1990;247:1465–8. - PubMed

LinkOut - more resources